Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from ”Nash

Nash Ensemble: A Birtwistle Celebration review – an intense and poetic tribute

The Nash and BBC Singers selected poignant vocal and instrumental works in memory of the late composer, as well as the premiere of a new Simon Holt work honouring sculptor Richard Serra

The Guardian - UK

Classical home listening: Elisabeth Lutyens Piano Works; Tchaikovsky and Korngold string sextets and more

Classical home listening: Elisabeth Lutyens Piano Works; Tchaikovsky and Korngold string sextets and more

Martin Jones makes a persuasive case for an unfashionable British composer; Antonio Oyarzabal continues to champion forgotten female composers; and the Nash Ensemble hit 60 in style

The Guardian - UK

Nash Ensemble: Terezín-Theresienstadt review – incredibly moving survey of composers lost to the Holocaust

Nash Ensemble: Terezín-Theresienstadt review – incredibly moving survey of composers lost to the Holocaust

Works by Hans Krása, Viktor Ullmann, Pavel Haas and Gideon Klein were wonderfully performed, while Konstantin Krimmel gave a heart-rending account of of songs written in the ghetto-camp – an essential and unforgettable experience

The Guardian - UK

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Stellantis CEO sounds the alarm for the future of electric vehicle companies

Carlos Tavares has a lot to say about the future of the EV industry and he said some startup companies may not be around much longer.

Why Akero Therapeutics Lost More Than Half Its Value And Dragged Down 89bio

Shares of Akero Therapeutics and 89bio stock crashed Tuesday after Akero's treatment for the liver disease, NASH, fell short in a midstage study.

Investors Business Daily

Former Wall Street Darling Intercept Restructures After FDA Rejects Its Liver Drug

Intercept Pharmaceuticals said Friday it will restructure itself after the FDA rejected its liver disease treatment. ICPT stock sank.

Investors Business Daily

Pokémon Tournament canceled after players protest “absolute disrespect” shown by organizers

A high-profile Pokémon tournament has been called off in the wake of protests from disgruntled players.

inkl

Read news from The Economist, FT, and more,
with one subscription

Intercept Tumbles As Its Experimental NASH Drug Faces Yet Another Obstacle

Intercept Tumbles As Its Experimental NASH Drug Faces Yet Another Obstacle

Intercept Pharmaceuticals said Friday its experimental liver disease treatment will face an FDA panel in May, leading ICPT stock to tumble.

Investors Business Daily

Akero Therapeutics Wows Investors With Unexpected Win For Hepatitis Treatment

Akero Therapeutics Wows Investors With Unexpected Win For Hepatitis Treatment

Akero wowed investors Tuesday with midstage test results for a hepatitis treatment, and the biotech stock skyrocketed by triple digits.

Investors Business Daily

Analysts Believe Madrigal's Resmetirom Shows Impressive Overall Profile In Liver Fibrosis

Madrigal Pharmaceuticals Inc (NASDAQ:MDGL) presented multiple resmetirom abstracts at the European Association for the Study of the Liver's International Liver Congress. The data included new details on changes in FibroScan controlled attenuation parameter and liver stiffness measurement along with magnetic resonance elastography, which serves as critical non-invasive measures of liver stiffness and fibrosis. …

Regulatory Update On Intercept Pharma's Obeticholic Acid For NASH Delayed Again

Regulatory Update On Intercept Pharma's Obeticholic Acid For NASH Delayed Again

Intercept Pharmaceuticals Inc's (NASDAQ:ICPT) pre-submission meeting to discuss the marketing application for obeticholic acid (OCA) in NASH has been moved to July (vs. June scheduling). The update follows a recent request from the FDA that topline data from the REGENERATE reanalysis be provided to the agency for review before the meeting. SVB Leerink…

ORMP: Broadening IP Protection, Positive Physician Indicators & Studies Advancing

By M. Marin NASDAQ:ORMP READ THE FULL ORMP RESEARCH REPORT Broadening patent IP protection…

1

People

Harrison Birtwistle

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

Intercept Pharmaceuticals

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

231,383 stories

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play